Neurodegenerative Drugs

Global Neurodegenerative Drugs Market to Reach US$64.9 Billion by 2030

The global market for Neurodegenerative Drugs estimated at US$43.7 Billion in the year 2024, is expected to reach US$64.9 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Dopamine Agonist, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.7 Billion by the end of the analysis period. Growth in the Decarboxylase Inhibitors segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.9 Billion While China is Forecast to Grow at 10.9% CAGR

The Neurodegenerative Drugs market in the U.S. is estimated at US$11.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Neurodegenerative Drugs Market – Key Trends & Drivers Summarized

Why Is Drug Development for Neurodegenerative Diseases Receiving Renewed Clinical and Commercial Focus?

Neurodegenerative diseases—such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple system atrophy—represent one of the most urgent and complex challenges in global medicine. These disorders involve progressive neuronal degradation, resulting in cognitive, motor, and behavioral impairments that worsen over time and remain largely incurable. As aging populations rise globally, the incidence of these conditions is increasing dramatically, placing immense pressure on healthcare systems and caregivers. Consequently, the market for neurodegenerative drugs is witnessing a surge in interest from pharmaceutical companies, biotech firms, and public health institutions.

Historically, the drug pipeline for neurodegenerative disorders has been plagued by high attrition rates, limited efficacy, and safety concerns. However, breakthroughs in genetics, protein misfolding research, and neuroimmunology are now driving the development of disease-modifying therapies (DMTs) that target underlying pathophysiology rather than just symptomatic relief. Government incentives, fast-track designations, and public-private research initiatives are creating a favorable ecosystem for innovation. As the societal and economic burden of neurodegeneration escalates, drug developers are prioritizing this therapeutic area not only for its medical importance but also for its massive unmet market potential.

How Are Disease-Modifying Approaches and Novel Mechanisms Shaping the Future of Neurodegenerative Drug Therapies?

Recent advances in disease biology have shifted the focus of drug development from symptomatic management to disease-modifying interventions. For Alzheimer’s, monoclonal antibodies targeting beta-amyloid (e.g., aducanumab, lecanemab) and tau proteins are under clinical evaluation and conditional approvals. In Parkinson’s disease, alpha-synuclein-targeting immunotherapies, LRRK2 inhibitors, and dopamine receptor agonists are being studied to slow dopaminergic neuronal loss. Gene therapies, RNA-targeting drugs (like antisense oligonucleotides), and neurotrophic factor modulators are also being trialed across multiple conditions.

Small molecules targeting neuroinflammation, mitochondrial dysfunction, protein aggregation, and oxidative stress are expanding the scope of therapeutic mechanisms. Additionally, repurposed agents from oncology and immunology are entering late-stage trials in neurodegenerative settings. Biomarker-driven patient selection, digital phenotyping, and the use of fluid biomarkers (such as CSF neurofilament light chain) are improving trial efficiency and therapeutic personalization. These innovations mark a critical transition from palliation to potential alteration of disease trajectory, setting a new precedent for treatment expectations and regulatory pathways.

Which Patient Segments and Global Regions Are Driving Demand for Neurodegenerative Drugs?

The primary patient demographics for neurodegenerative drugs are older adults, especially those over 65, who represent the most affected cohort for Alzheimer’s and Parkinson’s. Early-onset and genetically predisposed populations are also being identified and monitored more closely through genomic screening, enabling earlier intervention strategies. The increasing diagnosis of mild cognitive impairment (MCI) and prodromal Parkinson’s is expanding the treatment window and driving demand for early-stage therapeutics.

Geographically, North America dominates the neurodegenerative drug market due to robust R&D infrastructure, high diagnostic penetration, and early adoption of novel therapeutics. Europe follows with strong regulatory support for rare neurodegenerative conditions and coordinated dementia care initiatives. Asia-Pacific is emerging as a growth frontier, particularly in Japan and China, where rapidly aging populations and increasing investment in neurological research are accelerating demand. Global awareness campaigns, caregiver support programs, and telemedicine expansion are facilitating access and adherence, especially in under-resourced regions.

What Is Fueling Long-Term Growth and Innovation in the Neurodegenerative Drugs Market?

The growth in the neurodegenerative drugs market is driven by demographic trends, advances in neuroscience, and increasing public and private investment in brain health. Aging societies are catalyzing funding for early intervention strategies and long-term disease management solutions. Regulatory bodies are offering accelerated review pathways, conditional approvals, and orphan drug incentives to encourage therapeutic innovation in high-risk, high-failure domains. Meanwhile, venture capital and big pharma partnerships are funneling resources into neurology startups with novel mechanisms of action.

Digital biomarkers, AI-assisted drug discovery, and patient stratification tools are improving trial outcomes and enabling precision neurotherapeutics. Real-world evidence (RWE) and post-market surveillance are being used to support regulatory decisions and inform reimbursement strategies. As the societal toll of neurodegeneration intensifies, therapeutic approaches are expanding to include combination regimens, neurorestorative strategies, and non-invasive neuromodulation. Collectively, these factors ensure that neurodegenerative drugs will remain at the forefront of innovation, investment, and healthcare transformation in the coming decades.

SCOPE OF STUDY:

The report analyzes the Neurodegenerative Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Dopamine Agonist, Decarboxylase Inhibitors, Cholinesterase Inhibitors, Immunomodulators, Other Drug Classes); Indication (Parkinson`s Disease, Alzheimer`s Disease, Multiple Sclerosis, Other Indications); Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores & Retail Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• AC Immune SA
• Acorda Therapeutics, Inc.
• Alector, Inc.
• Alnylam Pharmaceuticals, Inc.
• Amylyx Pharmaceuticals, Inc.
• Biogen Inc.
• Boehringer Ingelheim GmbH
• CervoMed Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.